Background: Diabetes mellitus (DM) type 2 is a metabolic disorder that needs special attention because it can damage several organs if the severity increases. One of the treatments for diabetes mellitus (DM) type 2 is by inhibiting Dipeptidyl peptidase 4 (DPP-IV) with vildagliptin to prolong the hypoglycemic effect of GLP-1 and GIP. Objective: In the search for candidate compounds as new antidiabetic compounds, an in silico test with molecular docking was carried out to predict the antidiabetic activity of 10 Moringa oleifera Lam (MO) plant compounds at the DPP-IV receptor (PDB ID: 6B1E). Method: The study was conducted using the molecular docking method. Result: Validation of the vildagliptin DPP-IV ligand obtained free energy values of -9.27 kcal/mol and RMSD 1.49 Å (RMSD < 2 Å), then tested with 10 test compounds obtained 8 test compounds that have the potential to be antidiabetic. Conclusion: Serpentine compounds have better potential as an antidiabetic drug than other target compounds because they have the closest Gibbs energy (∆G) value to the natural ligand of Vidaglibtin, which is -7.90 kcal/mol. This value is still lower than the free energy of vildagliptin, which is -9.37 kcal/mol. Therefore further testing is needed to ensure the potential of the compound as a candidate for antidiabetic drugs.
Coronary Heart Disease (CHD) is a heart disorder caused by blockage of blood vessels. CHD can bedetected by Myocardial Perfusion Imaging (MPI). MPI is performed by injecting a radiopharmaceuticalinto the patient's body. 99mTc-sestamibi is a radiopharmaceutical that is commonly used in MPI.Sestamibi is available in the form of a multidose vial, but the cost of the examination will be expensiveif it is only used for one patient. Cost effectiveness can be increased by fractionating the sestamibi kitbefore labelled by 99mTc. 99mTc-sestamibi needs to be tested for quality control before it is administeredto the patients. One of the tests is the radiochemical purity test. The aim of this study was to determinethe radiochemical purity of the fractionated sestamibi kit labelled by 50 mCi 99mTc. 2 vials of sestamibikit were fractionated by adding 5 mL of 0.9% NaCl solution to each vial and divided into 10 new vials.Radiochemical purity was measured using the thin layer chromatography (TLC) method. The resultsof this study indicated that all samples had radiochemical purity of 100% up to 6 hours after labelling.
Coronary Heart Disease (CHD) is a heart disorder caused by blockage of blood vessels. CHD can bedetected by Myocardial Perfusion Imaging (MPI). MPI is performed by injecting a radiopharmaceuticalinto the patient's body. 99mTc-sestamibi is a radiopharmaceutical that is commonly used in MPI.Sestamibi is available in the form of a multidose vial, but the cost of the examination will be expensiveif it is only used for one patient. Cost effectiveness can be increased by fractionating the sestamibi kitbefore labelled by 99mTc. 99mTc-sestamibi needs to be tested for quality control before it is administeredto the patients. One of the tests is the radiochemical purity test. The aim of this study was to determinethe radiochemical purity of the fractionated sestamibi kit labelled by 50 mCi 99mTc. 2 vials of sestamibikit was fractionated by adding 5 mL of 0.9% NaCl solution to each vial and divided into 10 new vials.Radiochemical purity was measured using the thin layer chromatography (TLC) method. The resultsof this study indicated that all samples had radiochemical purity of 100% up to 6 hours after labellingKeywords: Radiopharmaceutical, 99mTc-sestamibi, fractionation, radiochemical purity
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.